［Abstract］　Pulmonary hypertension is a serious disease with poor prognosis, which can develop into right heart failure, and lead to death. Timely and accurate assessment of right heart function is of great significance for judging the severity of the disease, making treatment plans and assessing the prognosis of the disease. In this review, the commonly used examination techniques, indicators and clinical significance of right heart function assessment are introduced, including electrocardiogram, echocardiography, cardiac magnetic resonance, computed tomography scanning, etc. Echocardiography is an important screening method. Tricuspid annular plane systolic excursion(TAPSE), right ventricular index of myocardial performance(RIMP) and fractional area change(FAC) can reflect the right heart function more accurately. Cardiac magnetic resonance is the gold standard for noninvasive assessment of right heart function. Computed tomography scanning technology can reflect not only the right heart function, but also other structures in the chest, which is helpful to find the causes of pulmonary hypertension.]]> 2020/9/30 16:48:19 JIANG Kai-yu, SU Xin, GUO Zhao-xia, et al. 6true ［Abstract］　Pulmonary arterial hypertension(PAH) is a pulmonary vascular disease associated with high mortality and is characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance. If not treated in time, PAH will eventually lead to right ventricular failure and death. Over the past few decades, the emergence of targeted drugs has significantly improved the outcomes of the patients, but the current treatments are still difficult to halt or reverse the progression of PAH. PAH remains a fatal disease, making it particularly important to develop new targets for drug therapy. Currently, drugs targeting at potentially reversing pulmonary vascular remodeling caused by abnormal proliferation, migration and apoptosis of pulmonary artery smooth muscle cells are becoming a research hotspot, which brings new hope for curing PAH. In this paper, the current status and prospects of PAH targeted drugs treatment is reviewed, and the evidence-based medical evidence for PAH targeted treatment is discussed.]]> 2020/9/30 16:48:19 CHEN Yu-si, LI Jiang 5true ［Abstract］　Pulmonary arterial hypertension(PAH) is a chronic and fatal disease. Although the existing agents for PAH have certain therapeutic effects, their prognoses are still unsatisfactory, and new treatment methods need to be explored. Therapeutic vaccines offer a novel approach to treating PAH. The abnormal activation of endothelin(ET) system, especially ET-1 and endothelin A receptor(ETAR) is closely related to the pathogenesis of PAH, and ETAR is an ideal target of PAH therapeutic vaccine. Recently, we have successfully developed ETRQβ-002, a PAH therapeutic vaccine targeting ETAR, which can significantly reduce pulmonary artery pressure in two types of PAH-model animals, and improve or even reverse the remodeling of pulmonary arterioles and right ventricular hypertrophy, and no obvious target organ immune damage and abnormal liver and kidney function are found, indicating that ETRQβ-002 is an effective and safe therapeutic vaccine for PAH.]]> 2020/9/30 16:48:19 ZHOU Zi-hua 4true ［Abstract］　Chronic thromboembolic pulmonary hypertension(CTEPH) belongs to the fourth major classification of pulmonary hypertension(PH), and is the only PH that may be cured at present. Without intervention, the long-term prognosis of CTEPH is poor. Therefore, it is very important to make a clear diagnosis and active treatment. Compared with computed tomography(CT) pulmonary angiography, ventilation-perfusion scintigraphy(V/Q scintigraphy) is highly sensitive in diagnosis of CTEPH. The prognosis of CTEPH is closely related to its treatment decisions: all the patients need lifelong anticoagulation, and riociguat is the only targeted drug currently approved for the treatment of CTEPH. Surgical treatment depends on the CTEPH thromboembolic organization sites: for the thromboembolism at the proximal end of the pulmonary artery, pulmonary thromboendarterectomy is feasible, and the cure rate is high, and the postoperative recovery and the long-term prognosis are better; if the lesion site is in the middle part, balloon pulmonary angioplasty(BPA) can be tried, and the balloon dilatation usually needs to be carried out gradually in stages, and the patient′s activity tolerance is significantly improved after dilatation. In addition, balloon dilatation is also used for residual PH after surgical thromboendarterectomy or PH recurrence. If the lesion is located at the end of pulmonary vessels, conservative treatment with drugs is the only option. Combined therapy with multiple treatment methods may be the development direction of CTEPH treatment in the future.]]> 2020/9/30 16:48:19 LONG Yu-liang, GUAN Li-hua, ZHOU Da-xin 3true ［Abstract］　Chronic thromboembolic pulmonary hypertension(CTEPH) is a potentially lethal outcome of pulmonary embolism. At present, pulmonary endarterectomy(PEA) is the preferred treatment method for CTEPH, but many factors limit its clinical application and development.For CTEPH patients who can not be treated with PEA, percutaneous balloon pulmonary angioplasty(BPA) is a new interventional therapy developed rapidly in recent years, which can improve the clinical symptoms, reduce the pulmonary artery pressure and pulmonary vascular resistance of the patients, and improve their prognoses.]]> 2020/9/30 16:48:19 HONG Cheng, CHEN Hai-ming 2true ［Abstract］　Pulmonary arterial hypertension(PAH) is characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, which may lead to right heart failure and death. Almost all types of connective tissue disease(CTD) can be complicated with PAH, which is called connective tissue disease-related pulmonary arterial hypertension(CTD-PAH). CTD is the second leading cause of secondary PAH. PAH caused by systemic sclerosis is the most common in foreign countries, while PAH caused by systemic lupus erythematosus is the most common in China. PAH can complicate the clinical diagnosis and treatment of CTD and significantly increase the mortality of CTD patients. Exploring the pathogenesis of CTD-PAH and standardizing the diagnosis and treatment of CTD-PAH are helpful to improve the prognosis of the patients with CTD-PAH.]]> 2020/9/30 16:48:19 WANG Meng-jie, YANG Ying-xia, JI Qing-wei 1true